PANTOPRAZOLE SODIUM DELAYED RELEASE- pantoprazole sodium delayed release tablet, delayed release 
Northwind Pharmaceuticals


NDC: 51655-500-52

MFG: 0378-6689-10

Pantoprazole Sodium Delayed Release 40 MG

30 Tablets

Rx only


Exp. Date:

Each film-coated tabler contains: pantoprazole sodium, USP equivalent to 40 mg of pantoprazole

Dosage: See package insert

Store at 66-77 degrees F.

Store in a tight, light-resistant container (See USP). Keep out of the reach of children.

Mfg for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 USA Made in India Lot#:

Repackaged by: Northwind Pharmaceuticals, Indianapolis, IN 46256

Pantoprazole 51655-500

Indications and Usage

Pantoprazole is a proton pump inhibitor indicated for the following:

•Short-term Treatment of Erosive Esophagitis Associated with Gastroesophageal Reflux Disease (GERD).

•Maintenance of Healing of Erosive Esophagitis.

•Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome.

Warnings and Precautions

•Symptomatic response does not preclude presence of gastric malignancy.

•Atrophic gastritis has been noted with long-term therapy.

•PPI therapy may be associated with increased risk of Clostridium difficile associated diarrhea.

•Bone Fracture: Long-term and multiple daily dose PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist or spine.

•Hypomagnesemia has been reported rarely with prolonged treatment with PPIs

Adverse Reactions

The most frequently occurring adverse reactions are as follows:

•For adult use (> 2%) are headache, diarrhea, nausea, abdominal pain, vomiting, flatulence, dizziness, and arthralgia.

To report SUSPECTED ADVERSE REACTIONS, contact Mylan Pharmaceuticals Inc. at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or

Drug Interactions

•Do not coadminister with atazanavir or nelfinavir.

•Concomitant warfarin use may require monitoring.

•May interfere with the absorption of drugs where gastric pH is important for bioavailability.

•May produce false-positive urine screen for THC.

•Methotrexate: Pantoprazole may increase serum level of methotrexate

Information describing use in pediatric patients with erosive esophagitis associated with GERD is approved for Wyeth Pharmaceuticals Inc.’s pantoprazole sodium delayed-release tablets. However, due to Wyeth Pharmaceuticals Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

pantoprazole sodium delayed release tablet, delayed release
Product Information
Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:51655-500(NDC:0378-6689)
Route of AdministrationORAL
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
Product Characteristics
ColoryellowScoreno score
FlavorImprint Code M;P9
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:51655-500-5230 in 1 BOTTLE, DISPENSING
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
Labeler - Northwind Pharmaceuticals (036986393)
Registrant - Northwind Pharmaceuticals (036986393)
NameAddressID/FEIBusiness Operations
Northwind Pharmaceuticals036986393repack(51655-500)

Revised: 6/2014
Document Id: abee16aa-a278-4e4e-bbce-3b2f0599ba2f
Set id: bf31d3db-ed75-4513-a3a9-a163b5a5dceb
Version: 1
Effective Time: 20140606
Northwind Pharmaceuticals